Jaguar Health (HAM:1JA) Growth Rank : 0 (As of Jun. 04, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Jaguar Health Growth Rank?

Jaguar Health has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Jaguar Health Growth Rank Related Terms

Thank you for viewing the detailed overview of Jaguar Health's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Jaguar Health (HAM:1JA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (HAM:1JA) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

JAGX:USA 1JAA:Germany

Address

200 Pine Street, Suite 400, San Francisco, CA, USA, 94104

Website

http://www.jaguar.health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Jaguar Health (HAM:1JA) Headlines

No Headlines